BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 2021. [PMID: 34453359 DOI: 10.1002/hep.32131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90. [PMID: 35248211 DOI: 10.1016/S2468-1253(22)00062-0] [Reference Citation Analysis]
2 Inoue J, Kobayashi T, Akahane T, Kimura O, Sato K, Ninomiya M, Iwata T, Takai S, Kisara N, Sato T, Nagasaki F, Miura M, Nakamura T, Umetsu T, Sano A, Tsuruoka M, Onuki M, Niitsuma H, Masamune A; THERME Study Group. Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. JCM 2022;11:2354. [DOI: 10.3390/jcm11092354] [Reference Citation Analysis]
3 Yoon EL, Jun DW. Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature. Gut Liver 2022;16:319-20. [PMID: 35551103 DOI: 10.5009/gnl220183] [Reference Citation Analysis]
4 Sumida Y. Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. Hepatol Res 2022;52:415-6. [PMID: 35591814 DOI: 10.1111/hepr.13762] [Reference Citation Analysis]
5 Zheng Q, Xue C, Gu X, Shan D, Chu Q, Wang J, Zhu H, Chen Z. Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development. Front Cell Dev Biol 2022;10:830702. [DOI: 10.3389/fcell.2022.830702] [Reference Citation Analysis]
6 Chen Y, Yang C, Chung C, Ho C, Chen W, Chien W. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10281-9] [Reference Citation Analysis]
7 Zaiou M, Amrani R, Rihn B, Hajri T. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines 2021;9:1256. [PMID: 34572442 DOI: 10.3390/biomedicines9091256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tsutsumi T, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. Hepatol Res 2022;52:317-9. [PMID: 35229393 DOI: 10.1111/hepr.13738] [Reference Citation Analysis]